Stivarga (regorafenib) — Medica
Hepatocellular carcinoma
Initial criteria
- age ≥ 18 years
- previously treated with one systemic regimen (e.g., atezolizumab, bevacizumab, sorafenib, lenvatinib, nivolumab, tremelimumab, durvalumab)
Approval duration
1 year